Kuehn Law Encourages MORF, AMBC, INFN, and BEST Investors to Contact Law Firm
10 juil. 2024 08h03 HE
|
KUEHN LAW, PLLC
Kuehn Law Encourages MORF, AMBC, INFN, and BEST Investors to Contact Law Firm
MORF REMINDER: Robbins LLP is Investigating the Officers and Directors of Morphic Holdings, Inc.
07 déc. 2023 13h23 HE
|
Robbins LLP
MORF REMINDER: Robbins LLP is Investigating the Officers and Directors of Morphic Holdings, Inc
MORF SHAREHOLDERS: Investors of Morphic Holdings, Inc. Should Contact Robbins LLP for Information About Our Investigation
27 nov. 2023 18h52 HE
|
Robbins LLP
Investors of Morphic Holdings, Inc. Should Contact Robbins LLP for Information About Our Investigation
Morphic Holding, Inc. Investors Should Contact Robbins LLP for Information About Our Investigation of MORF
21 nov. 2023 16h11 HE
|
Robbins LLP
Morphic Holding, Inc. Investors Should Contact Robbins LLP for Information About Our Investigation of MORF
Morphic to Present at November Investor Conferences
10 nov. 2023 08h00 HE
|
Morphic Therapeutic
WALTHAM, Mass., Nov. 10, 2023 (GLOBE NEWSWIRE) -- Morphic Therapeutic (Nasdaq: MORF), a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious...
Morphic Corporation: Company Investigated by the Portnoy Law Firm
06 nov. 2023 16h24 HE
|
Portnoy Law
Investors can contact the law firm at no cost to learn more about recovering their losses LOS ANGELES, Nov. 06, 2023 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Morphic Holding, Inc....
Morphic Announces Participation in 2023 Wells Fargo Healthcare Conference
29 août 2023 08h00 HE
|
Morphic Therapeutic
WALTHAM, Mass., Aug. 29, 2023 (GLOBE NEWSWIRE) -- Morphic Therapeutic (Nasdaq: MORF), a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious...
Morphic Announces Corporate Highlights and Financial Results for the Second Quarter 2023
03 août 2023 07h05 HE
|
Morphic Therapeutic
-Reported positive topline results from EMERALD-1 study of MORF-057 in ulcerative colitis- -Continued enrollment on target in EMERALD-2 Phase 2b trial of MORF-057 in ulcerative colitis- -Greater...
Morphic to Present at the Jefferies Global Healthcare Conference
06 juin 2023 16h05 HE
|
Morphic Therapeutic
WALTHAM, Mass., June 06, 2023 (GLOBE NEWSWIRE) -- Morphic Therapeutic (Nasdaq: MORF), a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious...
Morphic Therapeutic Announces Closing of Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
05 mai 2023 10h30 HE
|
Morphic Therapeutic
WALTHAM, Mass., May 05, 2023 (GLOBE NEWSWIRE) -- Morphic Holding, Inc. (“Morphic”), a biopharmaceutical company developing a portfolio of oral integrin therapies for the treatment of serious chronic...